文献速递肝肾功能剂量调整

来特莫韦在肝功能不全受试者中的药代动力学与安全性

Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
PubMed 文献 · Br J Clin Pharmacol · 2017-08-27

该研究为1期开放标签平行组试验,比较中度(60 mg/日)和重度(30 mg/日)肝功能不全女性受试者与健康对照者多次口服来特莫韦的药代动力学。结果显示,中度肝功能不全使总来特莫韦暴露增加不到2倍,而重度肝功能不全使暴露增加约4倍;60/30 mg/日剂量在肝功能不全受试者中总体耐受良好。

要点

  • 中度肝功能不全使来特莫韦AUCτ,ss增至1.59倍(90%CI 0.98,2.57),暴露增加<2倍。
  • 重度肝功能不全使来特莫韦AUCτ,ss增至3.82倍(90%CI 2.94,4.97),暴露增加约4倍。
  • 来特莫韦60/30 mg/日在肝功能不全受试者中总体耐受良好。

核心结论

  • 中度肝功能不全使来特莫韦暴露增加不到2倍,重度肝功能不全使暴露增加约4倍。
  • 来特莫韦60/30 mg/日在肝功能不全受试者中总体耐受良好。

研究设计与样本

  • 1期、开放标签、平行组药代动力学与安全性比较试验。
  • 中度肝功能不全组(n=8)及匹配健康对照(n=9)接受来特莫韦60 mg/日,连续8天。
  • 重度肝功能不全组(n=8)及匹配健康对照(n=8)接受来特莫韦30 mg/日,连续8天。
  • 药代动力学参数由血样测定。

主要发现

  • 中度肝功能不全者总来特莫韦稳态Css,max为健康者的1.37倍(90%CI 0.87, 2.17)。
  • 中度肝功能不全者总来特莫韦稳态AUCτ,ss为健康者的1.59倍(90%CI 0.98, 2.57)。
  • 重度肝功能不全者总来特莫韦稳态Css,max为健康者的2.34倍(90%CI 1.91, 2.88)。
  • 重度肝功能不全者总来特莫韦稳态AUCτ,ss为健康者的3.82倍(90%CI 2.94, 4.97)。

临床怎么用

  • 临床对中度肝功能不全患者使用来特莫韦时,需注意暴露增加不到2倍。
  • 临床对重度肝功能不全患者使用来特莫韦时,需注意暴露增加约4倍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Human cytomegalovirus constitutes a prevalent and serious threat to immunocompromised individuals and requires new treatments. Letermovir is a novel viral-terminase inhibitor that has demonstrated prophylactic/pre-emptive activity against human cytomegalovirus in Phase 2 and 3 transplant trials. As unchanged letermovir is primarily excreted via the liver by bile, this trial aimed to assess the effect of hepatic impairment on letermovir pharmacokinetics. METHODS: Phase 1, open-label, parallel-group pharmacokinetic and safety comparison of multiple once-daily oral letermovir in female subjects with hepatic impairment and healthy matched controls. For 8 days, subjects with moderate hepatic impairment (n = 8) and their matched healthy controls (n = 9) received 60 mg letermovir/day and those with severe hepatic impairment (n = 8) and their matched healthy controls (n = 8) received 30 mg letermovir/day. Pharmacokinetic parameters were determined from blood samples. RESULTS: For subjects with moderate hepatic impairment, maximal observed concentration at steady state (Css,max ) and the area under the concentration vs. time curve over a dosing interval at steady state (AUCτ,ss ) for total letermovir were 1.37-fold (90% confidence interval: 0.87, 2.17) and 1.59-fold (0.98, 2.57) higher, respectively, than in healthy subjects. For subjects with severe hepatic impairment, Css,max and AUCτ,ss values of total letermovir were 2.34-fold (1.91, 2.88) and 3.82-fold (2.94, 4.97) higher, respectively, compared with healthy subjects. CONCLUSIONS: Moderate hepatic impairment increased exposure to letermovir <2-fold, while severe hepatic impairment increased letermovir exposure approximately 4-fold as compared with healthy subjects. Letermovir 60/30 mg/day was generally well-tolerated in subjects with hepatic impairment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Kropeit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol. 2017. PMID: 28722153. doi:10.1111/bcp.13376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。